CCX168
Sponsors
Amgen, Mario Negri Institute for Pharmacological Research
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated VasculitisAtypical Hemolytic Uremic SyndromeImmunoglobulin A NephropathySystemic Lupus Erythematosus (SLE)Vasculitis
Phase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants
CompletedNCT05984251
Start: 2009-12-21End: 2011-04-11Updated: 2023-08-09
A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
CompletedNCT05988021
Start: 2015-12-03End: 2016-05-25Updated: 2023-08-14
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
CompletedNCT05988008
Start: 2017-10-23End: 2018-09-20Updated: 2023-08-14
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
CompletedNCT06004947
Start: 2016-01-14End: 2016-06-10Updated: 2023-08-22
Phase 2
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
CompletedNCT01363388
Start: 2011-09-30End: 2016-01-31Updated: 2025-03-13
Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
CompletedNCT02384317
Start: 2015-03-27End: 2018-06-01Updated: 2025-03-13
Complement Inhibition in aHUS Dialysis Patients
TerminatedNCT02464891
Start: 2015-06-04End: 2017-07-13Updated: 2017-11-14